Safety of Long-Acting β-Agonists

  1. Dermot Ryan, MB, BCh, BAO
  1. From University of Aberdeen, Aberdeen, Scotland, United Kingdom.

    TO THE EDITOR:

    Salpeter and colleagues (1) seem to suggest that the cause for increased mortality from asthma is the use of LABAs. This class of medication became available in the United Kingdom in 1990 with the advent of salmeterol. Since that time, asthma mortality rates have decreased from approximately 2000 deaths per year to 1300 deaths …

    [Full Text of this Article]
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med November 7, 2006 vol. 145 no. 9 707
    1. » Excerpt
    2. Full Text
    3. Full Text (PDF)

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 17, 2009, 151 (10)
    1. Alert me to current issues